ETON PHARMACEUTIC

Eton Pharmaceuticals avoids costly active ingredient research by optimizing and exclusively marketing proven drugs for rare pediatric and metabolic conditions. New products are sold through the existing sales network to the same specialist physicians, allowing revenues to grow faster than operating costs. The company has reached profitability and plans to achieve long-term EBITDA margins above current levels through organic product expansion and targeted acquisitions. » Más en finanzen.net

Eton Pharmaceuticals’ stock rose to a record high of $64.29, bringing its market capitalization to about $1.81 billion. Over the past year the share price gained 271.39%, and revenue increased 81% over the last twelve months. In Q2 2026 adjusted EPS of $0.43 (consensus $0.15) and revenue of $37.6 million (expectation $26.88 million) beat estimates; InvestingPro nonetheless rates the stock as overvalued. » Más en de.investing.com

Eton Pharmaceuticals shares climbed to a record high of $55.07 and are currently trading at $54.43, well above the 52-week high of $50.18. In Q2 2026 the company reported adjusted earnings per share of $0.43 (expectation $0.15) and a record revenue of $37.6 million, driven by margin expansion and stronger sales in the rare diseases segment. Market capitalization is about $1.12 billion, trailing-12-month revenue growth is nearly 80%, while InvestingPro rates the stock as overvalued relative to its fair value. » Más en de.investing.com